(Q34256006)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

author

Udai Banerji

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

J M G Larkin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

T R Ferguson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

L M Pickering

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

K Edmonds

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

M G James

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

K Thomas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

B Berns

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

C de Boer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

M E Gore

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

14 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

1149-1153

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

Combination systemic therapy for advanced renal cell carcinoma

13 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967062

Sorafenib in advanced clear-cell renal-cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967062

TNF-alpha in promotion and progression of cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967062

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967062

Tumor necrosis factor or tumor promoting factor?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967062

The TNF and TNF receptor superfamilies: integrating mammalian biology

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967062

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967062

Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967062

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967062

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605889

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605889

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605889

Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967062

Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20842130

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6605889

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20842130%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

PubMed publication ID

20842130

1 reference